Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Next Previous
Trial Profile

A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OPC 1 (Primary) ; Tacrolimus
  • Indications Spinal cord injuries
  • Focus Adverse reactions; Proof of concept
  • Acronyms SCi-STAR; SCiSTAR
  • Sponsors Asterias Biotherapeutics; Lineage Cell Therapeutics

    • Most Recent Events

    • 11 Sep 2023 According to an Lineage Cell Therapeutics media release, data from this study will be present at the 2023 International Spinal Research Trust (ISRT) Network Meeting, being held September 14 to 16, 2023, at the Holiday Inn Regent's Park, London, UK.
    • 01 Dec 2022 Results assessing the safety of 3 escalating doses of oligodendrocyte progenitor cells (LCTOPC1) administered at a single time point between 21 and 42 days postinjury to participants with subacute cervical spinal cord injuries, published in the Journal of Neurosurgery - Spine.
    • 11 Aug 2022 According to an Lineage Cell Therapeutics media release, the company expect to report additional OPC1 manuscript focused on MRI data.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top